Picart T, Berhouma M, Dumot C, Pallud J, Metellus P, Armoiry X, Guyotat J
Service de neurochirurgie D, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France; Inserm 1052, UMR 5286,Team ATIP/AVENIR Transcriptomic diversity of stem cells, centre de cancérologie de Lyon, centre Léon-Bérard, 69008 Lyon, France.
Service de neurochirurgie D, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France; CREATIS Laboratory, Inserm U1206, UMR 5220, université de Lyon, 69100 Villeurbanne, France.
Neurochirurgie. 2019 Aug;65(4):164-177. doi: 10.1016/j.neuchi.2019.04.005. Epub 2019 May 21.
When feasible, the surgical resection is the standard first step of the management of high-grade gliomas. 5-ALA fluorescence-guided-surgery (5-ALA-FGS) was developed to ease the intra-operative delineation of tumor borders in order to maximize the extent of resection.
A Medline electronic database search was conducted. English language studies from January 1998 until July 2018 were included, following the PRISMA guidelines.
5-ALA can be considered as a specific tool for the detection of tumor remnant but has a weaker sensibility (level 2). 5-ALA-FGS is associated with a significant increase in the rate of gross total resection reaching more than 90% in some series (level 1). Consistently, 5-ALAFGS improves progression-free survival (level 1). However, the gain in overall survival is more debated. The use of 5-ALA-FGS in eloquent areas is feasible but requires simultaneous intraoperative electrophysiologic functional brain monitoring to precisely locate and preserve eloquent areas (level 2). 5-ALA is usable during the first resection of a glioma but also at recurrence (level 2). From a practical standpoint, 5-ALA is orally administered 3 hours before the induction of anesthesia, the recommended dose being 20 mg/kg. Intra-operatively, the procedure is performed as usually with a central debulking and a peripheral dissection during which the surgeon switches from white to blue light. Provided that some precautions are observed, the technique does not expose the patient to particular complications.
Although 5-ALA-FGS contributes to improve gliomas management, there are still some limitations. Future methods will be developed to improve the sensibility of 5-ALA-FGS.
在可行的情况下,手术切除是高级别胶质瘤治疗的标准第一步。5-氨基乙酰丙酸荧光引导手术(5-ALA-FGS)的开发是为了便于术中勾勒肿瘤边界,以最大限度地扩大切除范围。
进行了Medline电子数据库检索。按照PRISMA指南,纳入了1998年1月至2018年7月的英文研究。
5-ALA可被视为检测肿瘤残余的一种特定工具,但敏感性较低(2级)。5-ALA-FGS与大体全切除率的显著提高相关,在某些系列中达到90%以上(1级)。一致地,5-ALA-FGS可改善无进展生存期(1级)。然而,总生存期的获益更具争议。在明确功能区使用5-ALA-FGS是可行的,但需要同时进行术中脑电生理功能监测,以精确定位和保留明确功能区(2级)。5-ALA可在胶质瘤首次切除时使用,也可在复发时使用(2级)。从实际角度来看,5-ALA在麻醉诱导前3小时口服,推荐剂量为20mg/kg。术中,手术操作通常是先进行中央减压,然后进行周边剥离,在此过程中外科医生从白光切换到蓝光。只要注意一些预防措施,该技术不会使患者面临特殊并发症。
尽管5-ALA-FGS有助于改善胶质瘤的治疗,但仍存在一些局限性。未来将开发方法以提高5-ALA-FGS的敏感性。